Cited by 241Axon Guidance and Neuronal SignalingCell death mechanisms and regulationMechanisms of cancer metastasis

Netrin-1 expression confers a selective advantage for tumor cell survival in metastatic breast cancer

Open access
Fitamant, Julien, Guenebeaud, Céline, Coissieux, Marie-May, Guix, Catherine, Treilleux, Isabelle, Scoazec, Jean-Yves, Bachelot, Thomas, Bernet, Agnès +1 more·2008·Proceedings of the National Academy of Sciences

Abstract

Netrin-1, an axon navigation cue was proposed to play a crucial role during colorectal tumorigenesis by regulating apoptosis. The netrin-1 receptors DCC and UNC5H were shown to belong to the family of dependence receptors that share the ability to induce apoptosis in the absence of their ligands. Such a trait confers on these receptors a tumor suppressor activity. Expression of one of these dependence receptors at the surface of a tumor cell is indeed speculated to render this cell dependent on ligand availability for its survival, hence inhibiting uncontrolled cell proliferation or metastasis. Consequently, it is a selective advantage for a tumor cell to lose this dependence receptor activity, as previously described with losses of DCC and UNC5H expression in human cancers. However, the model predicts that a similar advantage may be obtained by gaining autocrine expression of the ligand. We describe here that, unlike human nonmetastatic breast tumors, a large fraction of metastatic breast cancers overexpress netrin-1. Moreover, we show that netrin-1-expressing mammary metastatic tumor cell lines undergo apoptosis when netrin-1 expression is experimentally decreased or when decoy soluble receptor ectodomains are added. Such treatments prevent metastasis formation both in a syngenic mouse model of lung colonization of a mammary cancer cell line and in a model of spontaneous lung metastasis of xenografted human breast tumor. Thus, netrin-1 expression observed in a large fraction of human metastatic breast tumors confers a selective advantage for tumor cell survival and potentially represents a promising target for alternative anticancer therapeutic strategies.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.0709810105

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

1 retracted

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Fitamant, J., Guenebeaud, C., Coissieux, M.-M., Guix, C., Treilleux, I., Scoazec, J.-Y., Bachelot, T., Bernet, A., & Mehlen, P.
Affiliations
  • Centre National de la Recherche Scientifique (FR)
  • Inserm (FR)
  • Lyon 1 Université (FR)
Corresponding author
Mehlen, Patrick
Venue
Proceedings of the National Academy of Sciences
Published
2008-03-25
Volume
105
Issue
12
Pages
4850-4855
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W1980116118
Cited by
241
References
36
Citations by year
2026: 7 · 2025: 10 · 2024: 12 · 2023: 12 · 2022: 18 · 2021: 10 · 2020: 16 · 2019: 15 · 2018: 17 · 2017: 13 · 2016: 13 · 2015: 11 · 2014: 14 · 2013: 15 · 2012: 13
FWCI
6.49
Type
journal article
Language
en
Open access
Locations
  • Proceedings of the National Academy of Sciences (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • European Commission
  • Agence Nationale de la Recherche
  • Institut National de la Santé et de la Recherche Médicale
  • Ligue Contre le Cancer
  • Centre National de la Recherche Scientifique
  • Institut National Du Cancer
  • Université de Lyon
  • Goddard Space Flight Center
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Axon Guidance and Neuronal Signaling
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mechanisms of cancer metastasis
Keywords
netrin-1, metastatic breast cancer, dependence receptors, DCC receptor, apoptosis, tumor cell survival, lung metastasis, tumor suppressor activity, cancer therapy targets
MeSH terms
Netrin-1, Animals, Breast Neoplasms, Cell Survival, Female, Humans, Lung Neoplasms, Neoplasm Metastasis, Neoplasm Transplantation, Nerve Growth Factors, Biomarkers, Tumor, Gene Expression Regulation, Neoplastic, Cell Death, Autocrine Communication, Reverse Transcriptase Polymerase Chain Reaction, Tumor Suppressor Proteins, Cell Line, Tumor, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review